🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

226 results for “Pfizer” Clear

  1. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  2. giroctocogene fitelparvovec

    Pfizer Ireland Pharmaceuticals Unlimited Company

    hemophilia A

    phase 3 small molecule active

    1 trial

  3. giroctocogene fitelparvovec, fidanacogene elaparvovec

    Pfizer Ireland Pharmaceuticals Unlimited Company

    hemophilia A, severe to moderately severe hemophilia B (FIX:C ≤ 2%)

    phase 3 small molecule active

    1 trial

  4. A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer

    Bristol-Myers Squibb / Pfizer EEIG

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  5. Avastin 25 mg/ml concentrate for solution for infusion., ACIDO VALPROICO E SODIO VALPROATO ratiopharm 500 mg compresse a rilascio prolungato, Oxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione, FLUOROURACILE PFIZER 50 mg/mL, solution à diluer pour perfusion, Capecitabina Glenmark 150 mg comprimidos recubiertos con película EFG

    Fondazione Telethon ETS

    Patients with ras-mutated metastatIc colorectal cancer

    phase 2 small molecule active

    1 trial

  6. BBP-398, CETUXIMAB, ADAGRASIB

    Bristol-Myers Squibb / Pfizer EEIG

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  7. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb / Pfizer EEIG

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  8. BINIMETINIB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, IPILIMUMAB, ENCORAFENIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma

    phase 2 small molecule active

    1 trial

  9. BMS-986470, BMS-986470, N/A, BMS-986470

    Bristol-Myers Squibb / Pfizer EEIG

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  10. BMS-986517

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  11. BMS-986523, BMS-986523

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  12. BMS-986525, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. BNT327 50 mg ml, BNT327 20 mg ml, IPILIMUMAB, ATEZOLIZUMAB, ATEZOLIZUMAB, BEVACIZUMAB, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  14. C4531002-A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult Participants with Moderate-Severe Atopic Dermatitis.

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-Severe Atopic Dermatitis

    phase 2 other active

    1 trial

  15. C4531029:A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-07275315 in Adult Participants with Inadequately Controlled Moderate-to-Severe Asthma

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Moderate-to-severe Asthma

    phase 2 other active

    1 trial

  16. CISPLATIN, Ipilimumab, PACLITAXEL, Nivolumab Subcutaneous, CARBOPLATIN, PEMETREXED

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  17. CISPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., PACLITAXEL, anti-NKG2A mAb, CARBOPLATIN, PEMETREXED DISODIUM

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. CT7001, PF-07850327 round

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  19. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, PACLITAXEL, TOPOTECAN, farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  20. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Roche Registration Limited

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Maplirpacept

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  22. DASATINIB, Dasatinib, dasatinib, dasatinib

    Bristol-Myers Squibb / Pfizer EEIG

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  23. DEXAMETHASONE, DEXAMETHASONE, LENALIDOMIDE, Empliciti 400 mg powder for concentrate for solution for infusion., LENALIDOMIDE, LENALIDOMIDE, LENALIDOMIDE

    Bristol-Myers Squibb / Pfizer EEIG

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. DIPHENHYDRAMINE HYDROCHLORIDE, PF-06835375 Injection

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Primary immune thrombocytopenia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources